Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants

Wes Onland; Martin Offringa; Anton van Kaam

doi:10.1002/14651858.CD002311.pub4

Cochrane Database of Systematic Reviews

Inhalación tardía de corticosteroides (≥ siete días) para reducir la displasia broncopulmonar

Información

DOI:

https://doi.org/10.1002/14651858.CD002311.pub4 Copiar DOI

Base de datos:

Cochrane Database of Systematic Reviews

Versión publicada:

24 agosto 2017see what's new

Tipo:

Intervention

Etapa:

Review

Grupo Editorial Cochrane:

Grupo Cochrane de Neonatología

Copyright:

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

Wes Onland

Correspondencia a: Department of Neonatology, Emma Children's Hospital AMC, University of Amsterdam, Amsterdam, Netherlands

[email protected]
Martin Offringa

Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, Canada
Anton van Kaam

Department of Neonatology, Emma Children's Hospital AMC, University of Amsterdam, Amsterdam, Netherlands

Contributions of authors

Dr Onland and Dr van Kaam have full access to all of the data in the review and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Onland, van Kaam
Acquisition of data: Onland, van Kaam
Analysis and interpretation of data: Onland, Offringa, van Kaam
Drafting of the manuscript: Onland, van Kaam
Critical revision of the manuscript for important intellectual content: Onland, Offringa, van Kaam
Stastical analysis: Onland
Study supervision: Offringa, van Kaam

Sources of support

Internal sources

Department of Neonatology, AMC, Amsterdam, Netherlands.
Department of Pediatric Clinical Epidemiology, AMC, Netherlands.

External sources

Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA.

Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201600005C.

Declarations of interest

Wes Onland: No financial disclosure to be declared. No potential conflicts of interest known.
Martin Offringa: No financial disclosure to be declared. No potential conflicts of interest known.
Anton van Kaam: No financial disclosure to be declared. No potential conflicts of interest known.

Acknowledgements

Dr P Lister, Dr R Iles, Dr B Shaw, Dr F Ducharme for writing the previous version of this review, 'Inhaled steroids for neonatal chronic lung disease'.

Dr DSchwartz, Dr T Giep, Prof M Silverman, and Dr S Brudno provided additional information for the previous version of this review.

Prof Silverman and Dr Jonsson provided precious additional data for this updated version of the review.

Ms D Haughton, Ms Y Montagne, Ms C Ovelman, Ms J Spano, and Prof R Soll of Cochrane Neonatal.

Version history

Published

Title

Stage

Authors

Version

2022 Dec 15

Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants

Review

Wes Onland, Martin Offringa, Anton Kaam

https://doi.org/10.1002/14651858.CD002311.pub5

2017 Aug 24

Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants

Review

Wes Onland, Martin Offringa, Anton van Kaam

https://doi.org/10.1002/14651858.CD002311.pub4

2012 Apr 18

Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants

Review

Wes Onland, Martin Offringa, Anton van Kaam

https://doi.org/10.1002/14651858.CD002311.pub3

2010 Jan 20

Inhaled steroids for neonatal chronic lung disease

Review

Paula Lister, Richard Iles, Ben NJ Shaw, Francine M Ducharme

https://doi.org/10.1002/14651858.CD002311.pub2

1999 Oct 25

Inhaled steroids for neonatal chronic lung disease

Review

Paula Lister, Richard Iles, Ben NJ Shaw, Francine Ducharme

https://doi.org/10.1002/14651858.CD002311

Differences between protocol and review

Given the paucity of data, we failed to perform the sensitivity analyses examining the potential influence of treatment variation (type and dose of inhalation corticosteroid, duration of treatment, and delivery system).

Notes

Editorial responsibility for the review 'Inhaled steroids for neonatal chronic lung disease' has been transferred to the Cochrane Neonatal Review Group from the Cochrane Airways Group.

A new team of review authors has been assigned: Dr Wes Onland, Dr Martin Offringa, and Dr Anton Van Kaam.

Keywords

MeSH

Medical Subject Headings (MeSH) Keywords

Medical Subject Headings Check Words

Humans; Infant, Newborn;

PICO

Population

Intervention

Comparison

Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Figure 1

Flow of inclusion of randomised controlled trials in different phases of search.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 2

Study flow diagram: review update.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Figure 4

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.1

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 1 Combined outcome mortality or bronchopulmonary dysplasia at 36 weeks PMA.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.2

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 2 Mortality at 28 days PNA.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.3

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 3 Mortality at 36 weeks PMA.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.4

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 4 Mortality at hospital discharge.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.5

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 5 Bronchopulmonary dysplasia at 28 days PNA.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.6

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 6 Bronchopulmonary dysplasia at 36 weeks PMA.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.7

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 7 Combined outcome mortality and bronchopulmonary dysplasia at 28 days PNA.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.8

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 8 Failure to extubate day 7.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.9

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 9 Failure to extubate day 14.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.10

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 10 Failure to extubate at the latest reported moment.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.11

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 11 Days of mechanical ventilation.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.12

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 12 Days of supplemental oxygen.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.13

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 13 Open‐label intravenous corticosteroids.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.14

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 14 Sepsis (clinical suspected or culture proven).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.15

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 15 Patent ductus arteriosus.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.16

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 16 Hypertension (> 2 SD).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.17

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 17 Necrotising enterocolitis.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.18

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 18 Intraventricular haemorrhage (any grade).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.19

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 19 Days of hospitalisation.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.20

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 20 Airway resistance.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Analysis 1.21

Comparison 1 Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants, Outcome 21 Dynamic lung compliance.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Summary of findings for the main comparison. Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants

Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants
Patient or population: preterm infants Setting: neonatal intensive care units Intervention: inhaled corticosteroids Comparison: placebo
Outcomes	*Anticipated absolute effects (95% CI)**		Relative effect (95% CI)	№ of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with inhaled corticosteroids
Combined outcome mortality or bronchopulmonary dysplasia at 36 weeks postmenstrual age	Study population		RR 1.10 (0.74 to 1.63)	30 (1 RCT)	⊕⊝⊝⊝ VERY LOW ^{1 2 3 4 5}
	533 per 1000	587 per 1000 (395 to 869)
Mortality at 36 weeks postmenstrual age	Study population		RR 3.00 (0.35 to 25.78)	61 (3 RCTs)	⊕⊕⊝⊝ LOW ^{1 2 5 6 7}
	0 per 1000	0 per 1000 (0 to 0)
Bronchopulmonary dysplasia at 36 weeks postmenstrual age	Study population		RR 1.00 (0.59 to 1.70)	30 (1 RCT)	⊕⊝⊝⊝ VERY LOW ^{1 2 3 4 5}
	600 per 1000	600 per 1000 (354 to 1000)
Open‐label intravenous corticosteroids	Study population		RR 0.51 (0.26 to 1.00)	74 (4 RCTs)	⊕⊝⊝⊝ VERY LOW ^{1 5 8 9 10}
	432 per 1000	320 per 1000 (216 to 476)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low quality: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
¹Risk of bias: No serious limitations. No downgrade. ²Indirectness: Head‐to‐head comparison. No downgrade. ³Publication bias: Only one trial was able to provide data for this outcome for ventilated and non‐ventilated infants separately. Downgraded one level. ⁴Inconsistency: Difference in effect estimates might be explained by inclusion of both ventilated and non‐ventilated infants. Downgraded one level. ⁵Imprecision: Total number of included infants less than optimal information size calculation. Downgraded one level. ⁶Inconsistency: No inconsistency detected. No downgrade. ⁷Publication bias: Only two of the eight included studies reported this outcome. Downgraded one level. ⁸Inconsistency: Included trials investigated different inhalation drugs. Downgraded one level. ⁹Indirectness: No serious limitations. No downgrade. ¹⁰Publication bias: Funnel plot is asymmetrical. Downgraded one level.

Summary of findings for the main comparison. Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants

Ir a la tabla de la revisión

Comparison 1. Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Combined outcome mortality or bronchopulmonary dysplasia at 36 weeks PMA Show forest plot	1	30	Risk Ratio (M‐H, Fixed, 95% CI)	1.10 [0.74, 1.63]

1.1 Ventilated infants	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	1.24 [0.87, 1.75]
1.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	0.5 [0.06, 3.91]
2 Mortality at 28 days PNA Show forest plot	2	51	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.14, 65.90]

2.1 Ventilated infants	2	41	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.14, 65.90]
2.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Mortality at 36 weeks PMA Show forest plot	3	61	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.35, 25.78]

3.1 Ventilated infants	3	51	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.35, 25.78]
3.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Mortality at hospital discharge Show forest plot	3	53	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.35, 25.78]

4.1 Ventilated infants	3	43	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.35, 25.78]
4.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Bronchopulmonary dysplasia at 28 days PNA Show forest plot	1	30	Risk Ratio (M‐H, Fixed, 95% CI)	0.93 [0.72, 1.21]

5.1 Ventilated infants	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.61, 1.29]
5.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.71, 1.41]
6 Bronchopulmonary dysplasia at 36 weeks PMA Show forest plot	1	30	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.59, 1.70]

6.1 Ventilated infants	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	1.14 [0.69, 1.90]
6.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	0.5 [0.06, 3.91]
7 Combined outcome mortality and bronchopulmonary dysplasia at 28 days PNA Show forest plot	1	30	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.85, 1.18]

7.1 Ventilated infants	1	20	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.83, 1.20]
7.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.71, 1.41]
8 Failure to extubate day 7 Show forest plot	5	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.66, 0.98]

9 Failure to extubate day 14 Show forest plot	2	27	Risk Ratio (M‐H, Fixed, 95% CI)	0.36 [0.10, 1.33]

10 Failure to extubate at the latest reported moment Show forest plot	6	90	Risk Ratio (M‐H, Fixed, 95% CI)	0.60 [0.45, 0.80]

11 Days of mechanical ventilation Show forest plot	3	45	Mean Difference (IV, Fixed, 95% CI)	3.42 [‐1.30, 8.13]

12 Days of supplemental oxygen Show forest plot	4	141	Mean Difference (IV, Fixed, 95% CI)	0.57 [‐5.92, 7.07]

12.1 Ventilated infants	4	100	Mean Difference (IV, Fixed, 95% CI)	5.53 [‐3.99, 15.05]
12.2 Non‐ventilated infants	2	41	Mean Difference (IV, Fixed, 95% CI)	‐3.74 [‐12.63, 5.14]
13 Open‐label intravenous corticosteroids Show forest plot	4	74	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.26, 1.00]

13.1 Ventilated infants	4	64	Risk Ratio (M‐H, Fixed, 95% CI)	0.51 [0.26, 1.00]
13.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
14 Sepsis (clinical suspected or culture proven) Show forest plot	5	107	Risk Ratio (M‐H, Fixed, 95% CI)	0.90 [0.50, 1.64]

14.1 Ventilated infants	5	97	Risk Ratio (M‐H, Fixed, 95% CI)	0.88 [0.44, 1.77]
14.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.36, 2.75]
15 Patent ductus arteriosus Show forest plot	1	30	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.16, 6.20]

15.1 Ventilated infants	1	30	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.16, 6.20]
16 Hypertension (> 2 SD) Show forest plot	1	27	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]

16.1 Ventilated infants	1	17	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
16.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
17 Necrotising enterocolitis Show forest plot	1	27	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]

17.1 Ventilated infants	1	17	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
17.2 Non‐ventilated infants	1	10	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
18 Intraventricular haemorrhage (any grade) Show forest plot	1	19	Risk Ratio (M‐H, Fixed, 95% CI)	0.6 [0.13, 2.82]

18.1 Ventilated infants	1	19	Risk Ratio (M‐H, Fixed, 95% CI)	0.6 [0.13, 2.82]
19 Days of hospitalisation Show forest plot	1	18	Mean Difference (IV, Fixed, 95% CI)	‐24.70 [‐41.75, ‐7.65]

19.1 Ventilated infants	1	18	Mean Difference (IV, Fixed, 95% CI)	‐24.70 [‐41.75, ‐7.65]
20 Airway resistance Show forest plot	1	18	Mean Difference (IV, Fixed, 95% CI)	21.40 [‐71.11, 113.91]

21 Dynamic lung compliance Show forest plot	1	18	Mean Difference (IV, Fixed, 95% CI)	‐0.22 [‐0.33, ‐0.11]

Comparison 1. Inhaled corticosteroids versus placebo to reduce bronchopulmonary dysplasia in preterm infants

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet

Scolaris Content Display Scolaris Content Display

Inhalación tardía de corticosteroides (≥ siete días) para reducir la displasia broncopulmonar

Información